Rep. Lisa C. McClain Purchases Shares of Sanofi (NASDAQ:SNY)

Key Points

• Representative Lisa C. McClain purchased between $1,001 and $15,000 in shares of Sanofi on August 4th, 2025, as disclosed in a recent filing.
• Sanofi reported earnings per share (EPS) of $0.90 for the last quarter, missing the consensus estimate of $0.96, while achieving revenues of $11.34 billion.
• Analysts maintain a favorable outlook on Sanofi, with a consensus rating of "Buy" and a target price of $62.67 per share.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Sanofi NASDAQ: SNY. In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Sanofi stock on August 4th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of ACI Worldwide NASDAQ: ACIW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Amedisys NASDAQ: AMED on 8/18/2025.
• Purchased $1,001 - $15,000 in shares of Kite Realty Group Trust NYSE: KRG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of JD.com NASDAQ: JD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of US Foods NYSE: USFD on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Agree Realty NYSE: ADC on 8/13/2025.

Sanofi Trading Up 1.5%

SNY traded up $0.71 during trading on Thursday, reaching $47.68. 2,078,521 shares of the stock traded hands, compared to its average volume of 2,599,121. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $117.08 billion, a PE ratio of 11.46, a P/E/G ratio of 1.11 and a beta of 0.51. The stock's 50-day moving average is $48.54 and its 200 day moving average is $51.00. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business's revenue was down 7.0% compared to the same quarter last year. During the same period last year, the company posted $1.73 EPS. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Sanofi by 124.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock valued at $1,344,000 after buying an additional 13,358 shares during the last quarter. Axxcess Wealth Management LLC increased its stake in shares of Sanofi by 130.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock worth $568,000 after purchasing an additional 5,794 shares during the last quarter. Ballentine Partners LLC increased its stake in shares of Sanofi by 68.7% during the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock worth $1,445,000 after purchasing an additional 10,617 shares during the last quarter. Sowell Financial Services LLC purchased a new stake in shares of Sanofi during the 1st quarter worth approximately $328,000. Finally, Farther Finance Advisors LLC increased its stake in shares of Sanofi by 66.2% during the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after purchasing an additional 2,476 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Guggenheim reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reissued an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $62.67.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.